Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11465256 | 0.98 | MAPT (0.60) | MAPTPARP1ALDH1A1NPC1GBA1 | |
| Hydrochloric Acid SCHEMBL29878602 | 0.98 | MAPT (0.55) | MAPTPARP1ALDH1A1NPC1GBA1 | |
| SCHEMBL2879929 | 0.83 | GSTP1 (0.58) | MAPTNPC1GBA1TNKSRAB9A | |
| SCHEMBL2101505 | 0.83 | AURKA (0.56) | MAPTPARP1ALDH1A1NPC1GBA1 | |
| SCHEMBL13736614 | 0.81 | AURKA (0.52) | MAPTPARP1ALDH1A1NPC1GBA1 | |
| SCHEMBL7227925 | 0.81 | MCL1 (0.42) | MAPTPARP1ALDH1A1NPC1GBA1 | |
| SCHEMBL11689636 | 0.81 | ALDH1A1 (0.47) | MAPTALDH1A1NPC1GBA1TNKS | |
| SCHEMBL25728205 | 0.81 | KDM4E (0.44) | MAPTNPC1GBA1TNKSDAO | |
| SCHEMBL12987176 | 0.81 | TNKS (0.44) | MAPTALDH1A1NPC1GBA1TNKS | |
| SCHEMBL2100160 | 0.81 | MAPT (0.58) | MAPTALDH1A1NPC1GBA1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716365-B | Application of N-substituted phenyl-2-pyridone compound or pharmaceutically acceptable salt thereof in treatment of pulmonary fibrosis | 大连理工大学 | 2024-03-01 | — | — | CN | claimed |
| CN-116655654-A | N-substituted phenyl-2-pyridone endoperoxide and application thereof | 大连理工大学 | 2023-08-29 | — | — | CN | claimed |
| CN-114716365-A | Application of N-substituted phenyl-2-pyridone compounds or pharmaceutically acceptable salts thereof in treating pulmonary fibrosis | 大连理工大学 | 2022-07-08 | — | — | CN | claimed |
| CN-114249987-A | Synthesis method of sulfonic ester group-containing pyridone azo disperse dye | 宁夏宁泰科技有限公司 | 2022-03-29 | — | — | CN | claimed |
| EP-1921065-B1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2010-10-20 | — | — | EP | claimed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | claimed |
| EP-1562602-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20050009835-A1 | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | THOMAS THOMAS NADACKAL (US) | 2005-01-13 | — | — | US | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2002-01-10 | — | — | US | claimed |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | CAMPBELL SIMON FRASER (GB) | 2001-11-22 | — | — | US | claimed |
| WO-2001070211-A2 | L-ARGININE AND PHOSPHODIESTERASE (PDE) INHIBITOR SYNERGISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | claimed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE2A | MAPT 3008/4885PARP1 1163/4885ALDH1A1 412/4885 |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE2A, PDE3B | MAPT 4197/4885PARP1 544/4885ALDH1A1 565/4885 |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE3B | MAPT 3116/4885PARP1 2718/4885ALDH1A1 618/4885 |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | MAPT 4665/4885PARP1 734/4885ALDH1A1 277/4885 |
| US-20050009835-A1 | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | PDE3A, PDE3B, PDE5A | MAPT 3318/4885PARP1 394/4885ALDH1A1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.